Pharmaceutical compositions based on anticholinergics and endothelin antagonists

Abstract

The present invention relates to novel pharmaceutical compositions based on anticholinergics and endothelin antagonists, processes for preparing them and their use in the treatment of respiratory tract diseases.

What is claimed is:  
     
         1 ) A pharmaceutical composition of matter which comprises as active substance one or more anticholinergic substances combined with as a second active substance one or more endothelin antagonists, wherein such anticholinergic substance and such endothelin antagonist may be in the form of an enantiomer, a mixture of enantiomers or in the form of a racemate, and further wherein the anticholinergic substance and such endothelin antagonist may be in the form of a solvate or a hydrate, all in combination with a pharmaceutically acceptable excipient.  
     
     
         2 ) The pharmaceutical composition of matter as recited in  claim 1  wherein the active substances are present in a single formulation.  
     
     
         3 ) The pharmaceutical composition of matter as recited in  claim 1  wherein the active substances are present in two separate formulations.  
     
     
         4 ) The pharmaceutical composition of matter as recited in  claim 1  wherein the anticholinergic substance is a salt of tiotropium, a salt of oxitropium or a salt of ipratropium.  
     
     
         5 ) The pharmaceutical composition of matter as recited in  claim 4  wherein the anticholinergic substance is the chloride, bromide, iodide, methane sulphonate or paratoluene sulphonate salt of tiotropium.  
     
     
         6 ) The pharmaceutical composition of matter as recited in  claim 5  wherein the anticholinergic substance is tiotropium bromide.  
     
     
         7 ) The pharmaceutical composition of matter as recited in  claim 4  wherein the anticholinergic substance is the chloride bromide, iodide, methane sulphonate or paratoluene sulphonate salt of oxitropium  
     
     
         8 ) The pharmaceutical composition of matter as recited in  claim 7  wherein the anticholinergic substance is oxitropium bromide.  
     
     
         9 ) The pharmaceutical composition of matter as recited in  claim 4  wherein the anticholinergic substance is the chloride, bromide, iodide, methane sulphonate or paratoluene sulphonate salt of ipratropium.  
     
     
         10 ) The pharmaceutical composition of matter as recited in  claim 9  wherein the anticholinergic substance is ipratropium bromide.  
     
     
         11 ) The pharmaceutical composition of matter as recited in  claim 1  wherein the endothelin antagonist is selected from tezosentan, bosentan, enrasentan, sixtasentan, T-0201, BMS-193884, K-8794, PD-156123, PD-156707, PD-160874, PD-180988, S-0139 and ZD-1611.  
     
     
         12 ) The pharmaceutical composition of matter as recited in  claim 11  wherein the endothelin antagonist is selected from tezosentan, bosentan, enrasentan, sixtasentan, T-0201 and BMS-193884.  
     
     
         13 ) The pharmaceutical composition of matter as recited in  claim 1  wherein the weight ratio of anticholinergic substance to endothelin antagonist is about 1:300 to about 50:1.  
     
     
         14 ) The pharmaceutical composition of matter as recited in  claim 13  wherein the weight ratio of anticholinergic substance to endothelin antagonist is about 1:250 to about 40:1.  
     
     
         15 ) The pharmaceutical composition of matter as recited in  claim 1  suitable for inhalation.